Chan Micah R, Thomas Christie P, Torrealba Jose R, Djamali Arjang, Fernandez Luis A, Nishimura Carla J, Smith Richard J H, Samaniego Millie D
Department of Medicine, Section of Nephrology, University of Wisconsin Hospitals and Clinics, Madison, WI, USA.
Am J Kidney Dis. 2009 Feb;53(2):321-6. doi: 10.1053/j.ajkd.2008.06.027. Epub 2008 Sep 21.
Atypical hemolytic uremic syndrome, or the nondiarrheal form of hemolytic uremic syndrome, is a rare disorder typically classified as familial or sporadic. Recent literature has suggested that approximately 50% of patients have mutations in factor H (CFH), factor I (CFI), or membrane cofactor protein (encoded by CD46). Importantly, results of renal transplantation in patients with mutations in either CFH or CFI are dismal, with recurrent disease leading to graft loss in the majority of cases. We describe an adult renal transplant recipient who developed recurrent hemolytic uremic syndrome 1 month after transplantation. Bidirectional sequencing of CFH, CFI, and CD46 confirmed that the patient was heterozygous for a novel missense mutation, a substitution of a serine reside for a tyrosine residue at amino acid 369, in CFI. This report reemphasizes the importance of screening patients with atypical hemolytic uremic syndrome for mutations in these genes before renal transplantation and shows the challenges in the management of these patients.
非典型溶血性尿毒症综合征,即溶血性尿毒症综合征的非腹泻型,是一种罕见疾病,通常分为家族性或散发性。近期文献表明,约50%的患者在补体因子H(CFH)、补体因子I(CFI)或膜辅助蛋白(由CD46编码)存在突变。重要的是,CFH或CFI存在突变的患者肾移植结果不佳,大多数病例中复发性疾病导致移植肾失功。我们描述了一名成年肾移植受者,其在移植后1个月发生复发性溶血性尿毒症综合征。对CFH、CFI和CD46进行双向测序证实,该患者在CFI中存在一个新的错义突变,即第369位氨基酸处酪氨酸残基被丝氨酸残基取代,为杂合子。本报告再次强调了在肾移植前对非典型溶血性尿毒症综合征患者进行这些基因突变筛查的重要性,并显示了这些患者管理中的挑战。